
|Videos|January 19, 2023
Efficacy and Safety of JAK inhibitors for AD
Author(s)Brett King, MD, PhD, Alexandra K. Golant, MD
Experts in atopic disease management review the efficacy and safety data of the JAK inhibitor class, highlighting the importance of time to treatment response and itch reduction.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
2
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
3
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
4
Top 5 Articles of the Week: December 7-12
5






















